Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Joseph TintelnotEray GoekkurtMascha BinderPeter Thuss-PatienceSylvie LorenzenJorge Riera KnorrenschildAlbrecht KretzschmarThomas EttrichUdo LindigLutz JacobaschDaniel PinkSalah-Eddin Al-BatranAxel HinkeSusanna Hegewisch-BeckerSven NilssonCarsten BokemeyerAlexander SteinPublished in: BMC cancer (2020)
NCT03409848 24.01.2018.
Keyphrases
- locally advanced
- phase iii
- squamous cell carcinoma
- phase ii
- open label
- rectal cancer
- neoadjuvant chemotherapy
- double blind
- clinical trial
- placebo controlled
- phase ii study
- radiation therapy
- study protocol
- epidermal growth factor receptor
- small cell lung cancer
- metastatic breast cancer
- metastatic colorectal cancer
- randomized controlled trial